대동맥류 시장은 2032년까지 CAGR 8.97%로 95억 3,000만 달러 규모로 성장할 것으로 예측되고 있습니다.
| 주요 시장 통계 | |
|---|---|
| 기준연도 2024년 | 47억 9,000만 달러 |
| 추정연도 2025년 | 52억 2,000만 달러 |
| 예측연도 2032년 | 95억 3,000만 달러 |
| CAGR(%) | 8.97% |
대동맥류 관리는 수술적 혁신, 인구 통계학적 변화, 진화하는 의료 서비스 제공 모델의 교차점에 위치하고 있습니다. 최근 임상 현장에서는 저침습적 치료로의 전환이 꾸준히 이루어지고 있으며, 영상기술과 의료기기의 발전이 동시에 진행되면서 수술 전후의 위험 감소에 대한 중요성이 높아지고 있습니다. 이러한 추세는 심혈관 질환의 동반질환 부담이 증가하는 고령화 사회를 배경으로 지속적인 임상 수요를 창출하는 동시에 안전성 확보, 장기적 내구성, 비용 효율적인 치료법 확립에 대한 관심이 높아지고 있습니다.
대동맥류 치료 환경은 기술의 성숙, 치료 환경의 변화, 이해관계자간의 가치 재정의로 인해 혁신적인 변화를 맞이하고 있습니다. 저침습적 혈관내 수복술은 영상 정확도 향상, 내비게이션 시스템, 기존에 수술이 불가능하다고 여겨졌던 부위에도 적용할 수 있는 모듈형 스텐트 그라프트 설계의 발전으로 인해 틈새 대안에서 많은 해부학적 형태의 표준 치료법으로 발전했습니다. 이러한 발전은 수술 전후 최적화 기술과 회복 촉진 프로토콜의 강화로 보완되어 입원 기간과 수술에 따른 합병증을 줄임으로써 임상적 판단의 계산식 자체를 변화시키고 있습니다.
2025년 시행된 관세 조정은 대동맥류 치료 관련 의료기기 제조업체, 의료 시스템, 유통업체들공급망 계산식에 새로운 변수를 도입했습니다. 혈관내 치료 및 개복 수술에 사용되는 많은 장치 및 부품은 전 세계에서 조달되며, 수입 관세의 변화는 스텐트 이식, 합성 도관, 보조 전달 부품의 착륙 비용 상승으로 이어질 수 있습니다. 이러한 비용 압박은 조달 프로세스 전반에 걸쳐 파급되어 병원 공급망 팀은 계약 재협상, 공급업체 다각화 전략 재평가, 특정 제조 및 멸균 공정의 현지화 가능성을 평가해야 하는 상황에 직면해 있습니다.
세분화 분석은 치료 선택, 기기 수요, 의료 서비스 프로바이더의 채택에 영향을 미치는 명확한 임상 채널과 상업적 고려 사항을 밝혀냅니다. 치료법에 따라 임상의는 환자의 해부학적 구조와 생리적 회복력을 고려하여 혈관내 수복술과 개복 수술을 비교 검토합니다. 혈관내 기술에서는 적용 범위를 확대하기 위해 첨단 전달 플랫폼을 갖춘 스텐트 이식 시스템이 점점 더 많이 활용되고 있으며, 개방형 수술에서는 내구성과 특정 해부학적 요구 사항이 접근 방식을 결정하는 상황에서 생체 도관과 합성 혈관 이식편 모두에 계속 의존하고 있습니다.
지역적 특성은 임상 관행, 인프라 구축 현황, 규제 요건에 큰 차이를 가져와 대동맥류 치료의 제공 방식과 제품 상용화에 영향을 미치고 있습니다. 북미와 남미에서는 강력한 민간 및 공공 보험 제도와 함께 저침습적 접근법이 강조되고 있습니다. 첨단 영상 네트워크와 높은 사례 수를 가진 3차 의료기관이 새로운 엔도그래프트와 복잡한 개방형 솔루션의 신속한 도입을 지원하고, 외래 진료 환경에서는 저위험 선택적 수술 사례가 점차 흡수되고 있습니다.
대동맥류 분야의 기업 전략은 지속적인 혁신, 임상적 근거 창출, 사업 규모 확대를 핵심으로 하고 있습니다. 주요 의료기기 개발 기업은 차세대 스텐트 이식 구조, 로우 프로파일 전달 시스템, 재료과학에 대한 투자를 우선순위로 두고 장기적인 치료 결과 개선과 해부학적 적응 범위 확대를 위해 노력하고 있습니다. 임플란트 성능과 첨단 내비게이션 기술, 수술 중 영상을 통합한 솔루션을 구현하기 위해 장치 혁신 기업과 수탁제조업체 또는 영상 기술 기업과의 전략적 제휴가 점점 더 보편화되고 있습니다.
업계 리더은 제품 혁신을 의료 서비스 동향, 규제 당국의 기대, 조달 현실에 부합하는 다각적인 전략을 채택해야 합니다. 첫째, 모듈형 및 해부학적 적응성이 있는 디바이스 플랫폼을 우선적으로 도입하여 시술의 복잡성을 줄이고, 저침습적 치료의 대상 환자군을 확대하여 다양한 의료현장에서 폭넓게 도입할 수 있도록 합니다. 다음으로, 강력한 실제 임상 데이터(RWE) 생성 및 레지스트리에 대한 투자를 통해 지불 기관의 수용을 촉진하고, 장기 안전성을 검증하며, 임상 실무 현실에 기반한 반복적인 제품 개선을 추진합니다.
본 Executive Summary를 지원하는 조사 방법은 엄격하고 증거에 기반한 지식을 확보하기 위해 정성적, 정량적 접근 방식을 통합하고 있습니다. 주요 입력 정보로 혈관외과 의사, 인터벤션 의사, 병원 조달 책임자, 의료기기 규제 전문가를 대상으로 전문가 인터뷰를 실시하여 현재 임상 실습, 기기 선호도, 도입 장벽을 파악했습니다. 이러한 임상의사 수준의 관점에 더해, 공급망 및 상업 부문 리더과의 논의를 통해 제조 고려사항, 유통 역학, 최근 무역 정책의 영향을 이해했습니다.
대동맥류 치료는 기술 혁신, 인구 통계학적 압력, 변화하는 의료 모델이 교차하면서 임상의, 제조업체, 의료 시스템 모두에게 기회와 복잡성을 동시에 가져다주는 전환점에 있습니다. 저침습적 혈관내 치료 전략으로의 전환은 치료 적응증 확대와 자원 배분에 변화를 가져오고 있으며, 이에 디바이스 개발 기업은 해부학적 문제와 장기적 내구성에 대응하는 특화형 혁신으로 대응하고 있습니다. 동시에, 무역 동향과 지불자의 면밀한 조사를 포함한 상업적, 정책적 발전은 조달 전략과 시장 진입 접근 방식에 영향을 미치고 있습니다.
The Aortic Aneurysm Market is projected to grow by USD 9.53 billion at a CAGR of 8.97% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2024] | USD 4.79 billion |
| Estimated Year [2025] | USD 5.22 billion |
| Forecast Year [2032] | USD 9.53 billion |
| CAGR (%) | 8.97% |
Aortic aneurysm management sits at the intersection of surgical innovation, demographic shifts, and evolving healthcare delivery models. Recent years have seen the steady migration of clinical preference toward less invasive therapies, concurrent advances in imaging and device technology, and a heightened emphasis on perioperative risk mitigation. These dynamics converge against a backdrop of an ageing population with rising cardiovascular comorbidity burden, creating sustained clinical demand while simultaneously intensifying the focus on safety, long-term durability, and cost-effective pathways for intervention.
Clinicians and health system leaders are now navigating a more complex therapeutic landscape in which endovascular options must be balanced against open repair approaches based on anatomical suitability, patient frailty, and access-to-care considerations. Device designers are responding with increasingly sophisticated stent graft architectures, refined delivery systems, and adjunctive tools to address challenging anatomies such as short-necked infrarenal aneurysms and complex thoracoabdominal lesions. At the same time, payors and hospital administrators are scrutinizing procedural site selection and resource utilization, prompting closer evaluation of ambulatory surgery centers and streamlined care protocols.
This executive summary synthesizes current clinical trends, regulatory and commercial shifts, and provider-level strategic implications to support clinicians, manufacturers, and investors in making informed decisions. The analysis emphasizes actionable insights into modality choice, device differentiation, end-user adoption patterns, and regional variations that are shaping the path forward for aortic aneurysm care.
The landscape of aortic aneurysm care is undergoing transformative shifts driven by technological maturation, changing care settings, and the reframing of value across stakeholders. Minimally invasive endovascular repair has progressed from a niche alternative to a default option for many anatomies, supported by improved imaging fidelity, navigation systems, and modular stent graft designs that address previously inoperable segments. These advances are complemented by perioperative optimization techniques and enhanced recovery protocols that reduce length of stay and procedural morbidity, thereby altering the calculus of clinical decision-making.
Concurrently, device innovation is moving toward personalized solutions, including fenestrated and branched endografts, low-profile delivery systems, and materials engineered for long-term durability and reduced thrombogenicity. These innovations expand candidacy for endovascular approaches, particularly among older or comorbid patients who would face higher risks with open surgical repair. The shift is not purely technological; it reflects an ecosystem change where multidisciplinary teams, including vascular surgery, interventional radiology, and cardiac surgery, increasingly collaborate to tailor therapy to patient-specific anatomy and risk profiles.
Health systems are also redefining care pathways, directing lower-risk elective procedures to ambulatory settings and employing telemedicine and remote monitoring for follow-up surveillance. This decentralization of care pressures device manufacturers to standardize training, simplify deployment, and ensure consistent outcomes across disparate settings. Lastly, regulatory emphasis on post-market surveillance and real-world evidence is prompting companies to invest in registries and longitudinal studies, which in turn inform clinical guidelines and payer coverage policies. Together, these shifts create both opportunity and competitive pressure for stakeholders to adapt strategy, investment, and product development roadmaps.
Tariff adjustments implemented in the United States in 2025 introduced a new variable into the supply chain calculus for medical device manufacturers, health systems, and distributors involved in aortic aneurysm care. Many devices and components used in endovascular and open surgical repairs are sourced globally, and changes in import duties can result in increased landed costs for stent grafts, synthetic conduits, and ancillary delivery components. These cost pressures ripple through procurement processes, prompting hospital supply chain teams to renegotiate contracts, reassess supplier diversification strategies, and evaluate the feasibility of localizing certain manufacturing or sterilization processes.
The cumulative impact of the tariff measures has prompted manufacturers to reassess their global sourcing footprints, with some prioritizing regional production hubs to mitigate exposure to trade fluctuations. For devices that rely on specialized raw materials or implants produced by a limited set of suppliers, tariffs have amplified the need for transparent cost structures and contingency planning. Health systems facing constrained operating budgets may respond by enhancing value-based contracting, extending device reuse policies within regulatory allowances, or prioritizing procedural modalities that demonstrate stronger cost-effectiveness in their local contexts.
Regulatory and reimbursement bodies have also taken notice, and the interplay between import duties and pricing has the potential to alter negotiations around bundled payments and procedural reimbursement. For international suppliers, tariff-induced pricing changes may slow market entry or shift commercialization timelines, particularly for high-complexity devices that require substantial clinical evidence prior to adoption. Ultimately, the 2025 tariff environment underscores the importance of supply-chain resilience, flexible manufacturing strategies, and closer collaboration between manufacturers and providers to preserve access to life-saving aortic aneurysm interventions while managing economic impacts.
Segmentation analysis reveals distinct clinical pathways and commercial considerations that influence treatment selection, device demand, and provider adoption. Based on treatment modality, clinicians weigh endovascular repair against open surgical repair by considering patient anatomy and physiological resilience; endovascular techniques increasingly leverage stent graft systems with advanced delivery platforms to expand applicability, while open surgical repair continues to rely on both biological conduits and synthetic vascular grafts where durability and specific anatomical requirements dictate approach.
When viewed through the lens of aneurysm type, abdominal aortic aneurysms and thoracic aortic aneurysms present different technical challenges and device requirements. Abdominal presentations are further stratified by infrarenal, juxtarenal, and suprarenal locations, each demanding unique fixation and sealing strategies, whereas thoracic presentations span ascending, descending, and thoracoabdominal segments that often require branched or fenestrated designs to preserve branch vessel integrity. These anatomical distinctions drive product development priorities, imaging protocols, and operator training needs.
End-user segmentation highlights divergent adoption curves and procedural settings. Ambulatory surgery centers, including cardiology-centered facilities and standalone surgery centers, are increasingly attractive for lower-risk, elective interventions that benefit from streamlined throughput and lower overhead. Conversely, hospitals, whether general, specialized vascular centers, or tertiary care institutions, maintain primacy for high-complexity cases and ruptured presentations that require multidisciplinary resources and critical care capabilities.
Device type segmentation isolates stent graft systems and synthetic vascular grafts as core product categories, each with unique regulatory pathways, sterilization requirements, and surgeon preferences. Indication-based segmentation differentiates elective repairs, where optimization of recovery and cost containment are priorities, from rupture repairs, which demand immediate access to robust devices and emergent care pathways. Patient demographics further nuance demand patterns, with an older cohort driving higher procedural volume and anatomical complexity; gender differences shape risk stratification and anatomical fit considerations, necessitating inclusive design and evidence generation across populations.
Regional dynamics produce meaningful variation in clinical practice, infrastructure readiness, and regulatory expectations that affect how aortic aneurysm care is delivered and how products are commercialized. In the Americas, there is a strong emphasis on minimally invasive approaches coupled with robust private and public payer systems; advanced imaging networks and high-volume tertiary centers support rapid adoption of novel endografts and complex fenestrated solutions, while ambulatory settings are progressively absorbing lower-risk elective cases.
Europe, Middle East & Africa present a heterogeneous landscape where western European markets emphasize guideline-driven adoption and centralized specialized vascular centers, and emerging markets across the Middle East and Africa grapple with infrastructure constraints and variable access to advanced devices. Regulatory alignment with regional authorities and investments in training and centers of excellence are critical to expanding reach across these diverse healthcare systems.
Asia-Pacific demonstrates accelerated uptake in innovation in several urbanized markets that combine high procedure volumes with expanding ambulatory infrastructures. Local manufacturing capacities and partnerships with global manufacturers are shaping access and price dynamics, while demographic trends and public health initiatives are increasing screening and early detection efforts. Across regions, differences in reimbursement structures, clinical guideline adoption, and workforce availability create distinct strategic imperatives for manufacturers and providers seeking sustainable growth and clinical impact.
Corporate strategy in the aortic aneurysm domain centers on sustained innovation, clinical evidence generation, and operational scale. Leading device developers prioritize investments in next-generation stent graft architectures, low-profile delivery systems, and materials science to improve long-term outcomes and broaden anatomical applicability. Strategic alliances between device innovators and contract manufacturers or imaging technology firms are increasingly common, enabling integrated solutions that combine implant performance with advanced navigation and intraoperative imaging.
Investment in post-market surveillance and real-world data initiatives has become a differentiator, supporting regulatory submissions, payer negotiations, and clinician confidence. Firms that can demonstrate comprehensive training programs, robust customer support, and streamlined logistics achieve higher penetration across ambulatory and hospital settings. Meanwhile, smaller and emerging medtech companies focus on niche innovations-such as branched configurations for complex thoracoabdominal repairs or biologically optimized graft materials-positioning themselves for acquisition or strategic partnerships with larger players.
Supply-chain agility and regional manufacturing presence influence competitive positioning, particularly in areas affected by trade policy shifts. Companies that proactively localize production or diversify supplier networks reduce exposure to tariff volatility and distribution bottlenecks. Additionally, those that invest in digital tools for follow-up surveillance, patient-reported outcomes, and remote monitoring create differentiated value propositions for health systems prioritizing longitudinal care and cost containment.
Industry leaders should adopt a multi-pronged strategy that aligns product innovation with care delivery trends, regulatory expectations, and procurement realities. First, prioritize modular and anatomically adaptable device platforms that reduce procedure complexity and expand the pool of patients eligible for less invasive treatment, thereby enabling broader adoption across diverse care settings. Second, invest in robust real-world evidence generation and registries to accelerate payer acceptance, validate long-term safety, and inform iterative product improvements that are grounded in clinical practice realities.
Third, strengthen supply-chain resilience by diversifying supplier bases, exploring regional production hubs, and developing contingency plans for component sourcing to mitigate the impact of trade policy shifts. Fourth, tailor commercial approaches to end-user segmentation by offering targeted training and support programs for ambulatory surgery centers, and by providing integrated clinical pathways for tertiary hospitals managing complex rupture cases. Fifth, collaborate with health systems to pilot bundled-care models and outcome-based contracts that align reimbursement with value delivered, thus improving access while demonstrating cost-effectiveness.
Finally, foster multidisciplinary clinician engagement and invest in education that promotes appropriate patient selection, surveillance protocols, and secondary prevention; this clinician-centric approach supports safer adoption of novel devices and strengthens long-term patient outcomes. These combined actions will position organizations to capture clinical and commercial opportunities while managing operational risks.
The research methodology underpinning this executive summary integrates qualitative and quantitative approaches to ensure rigorous, evidence-based insights. Primary inputs include expert interviews with vascular surgeons, interventionalists, hospital procurement leaders, and device regulatory specialists to capture current clinical practice, device preferences, and adoption barriers. These clinician-level perspectives are supplemented by discussions with supply-chain and commercial leaders to understand manufacturing considerations, distribution dynamics, and the implications of recent trade policies.
Secondary research involved a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and professional society position statements to validate clinical trends and device-specific performance characteristics. Where appropriate, registry data and published post-market surveillance reports were analyzed to assess safety signals and durability considerations, and findings were triangulated across multiple sources to enhance robustness. The segmentation framework was applied to map product types, indications, end-user settings, and patient cohorts to ensure that insights reflect the diversity of clinical pathways and commercial channels.
Finally, analytic rigor was maintained through cross-validation of thematic findings with independent experts and iterative refinement of conclusions to reflect both clinical nuance and commercial realism. This blended methodology supports actionable recommendations while acknowledging areas where evidence remains emergent and where ongoing surveillance will be required.
Aortic aneurysm care is at an inflection point where technological innovation, demographic pressures, and changing care models intersect to create both opportunity and complexity for clinicians, manufacturers, and health systems. The move toward minimally invasive endovascular strategies is broadening treatment candidacy and shifting resource allocation, while device developers respond with targeted innovations that address anatomical challenges and long-term durability. At the same time, commercial and policy developments, including trade dynamics and payer scrutiny, are influencing procurement strategies and go-to-market approaches.
Stakeholders that align product development with clinical evidence, invest in training and post-market surveillance, and build resilient supply chains will be best positioned to deliver patient-centered outcomes while achieving sustainable commercial performance. Embracing collaborative models with health systems and payers that emphasize value and outcomes will further enable access to advanced therapies and support the long-term viability of innovative solutions. As the landscape continues to evolve, continued monitoring of clinical data, regulatory developments, and regional care models will be essential to refine strategies and maintain alignment with emerging best practices.